Stomach cancer markers

Tsugani S, Tsuda M, Gey F and Watanabe S. 1992. Cross-sectional study with multiple measurements of biological markers for assessing stomach cancer risks at the population level. Environ Health Perspect 98 207-210. 

Doglioni C, Dei Tos AP, Laurino L, et al. A novel immunocytochemical marker for mesothelioma. Am I Surg Pathol. 1996 20 1037-1046. 5)ung KC, Park WS, Bae YM, et al. Immunoreactivity of CD99 in stomach cancer. ] Korean Med Sci. 2002 17 483-489. llMcCluggage WC, Maxwell P. Adenocarcinomas of various sites may exhibit immunoreactivity with anti-inhibin antibodies. Histopathology. 1999 216-220. 

Elevated levels of CKl have been demonstrated in prostate cancer and small cell carcinoma of the lung. Although it is also elevated in other malignancies, such as those of the breast, colon, ovary, and stomach, the clinical usefulness of CKl as a tumor marker requires further investigation. CK isoenzymes have been included in a prostate cancer panel, ProstAsure. ... 

H. pylori and the associated chronic inflammation are thought to initiate a cascade of events leading to atrophic gastritis, metaplasia, dysplasia, and cancer (Fignre 10.2). Once progression to dysplasia occurs, continued infection is probably uimecessary for continuation of the neoplastic sequence. In fact, the atrophic stomach may itself be unsuitable for continued H. pylori infection, and markers of infection may be negative at the time of diagnosis." ... 

MUCl-peptide (tumor marker for breast, stomach, lung, prostate, colorectal, and other cancers)... 

---